Recent Updates
Recently added Catalysts
ACRS Positive Sentiment

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

Key Takeaway: Aclaris Therapeutics will participate in the 2026 Cantor Global Healthcare Conference on September 10, 2026. CEO Dr. Neal Walker will engage in a fireside chat during the event. A live and archived webcast will be available on Aclaris' website for at least 30 days, allowing broader access to the discussion.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aclaris Therapeutics is actively participating in a significant healthcare conference.
  • The event provides a platform for Aclaris to showcase its innovations.
  • The webcast will be available for a month, increasing accessibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+181%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ATI-045
Phase 2 · Atopic Dermatitis

Full Press Release Details

WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris’ Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 wroberts@aclaristx.com

Frequently Asked Questions

When will Aclaris participate in the conference?

Aclaris will participate in the conference on September 10, 2026.

Who will represent Aclaris at the conference?

CEO Dr. Neal Walker will represent Aclaris at the conference.

Where can I watch the conference webcast?

The webcast will be available on Aclaris' website for at least 30 days.

What is the focus of Aclaris Therapeutics?

Aclaris focuses on developing novel product candidates for immuno-inflammatory diseases.

Last updated: Sep 3, 2026